Clinical Trial Update: A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin [Phase 3]

View source ↗

Summary

Phase 3 trial comparing subcutaneous epoetin products in patients with chronic renal failure on hemodialysis; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Renal Failure

Drugs mentioned

• Epoetin Hospira (epoetin alfa)
• Epogen (epoetin alfa)

Snippet

Sponsor: Pfizer | Conditions: Chronic Renal Failure, Chronic Kidney Disease | Phase 3 | Status: COMPLETED | Results posted: 2018-06-20